Contact Us
 • 
Home
Search 

About Us

What is the Liverpool ECMC?

The Liverpool ECMC is a collaboration between the University of Liverpool (Liverpool Cancer Trials Unit and Good Clinical Practice Laboratory Facility) and The Clatterbridge Cancer Centre NHS Foundation Trust. ECMC status was awarded to Liverpool in 2017 and is funded by Cancer Research UK and the National Institute for Health Research.

The Liverpool ECMC offers academic and industrial partners the opportunity to collaborate with leading academics and clinicans to develop translational research partnerships and deliver high quality, innovative early phase clinical trials, in key strategic areas.

ecmclogo
iontorrent

Liverpool ECMC Aims

The aims of the Liverpool ECMC are to:

  • Facilitate the transition of new drugs / combinations from early to late phase clinical trials with integrated biomarker development and to develop stratified approaches to more effective use of existing drugs.
  • Improve access and recruitment to early phase trials for cancer patients in Merseyside and Cheshire.
  • Increase Liverpool Cancer Trials Unit led early phase clinical trials.
  • Partner with the ECMC Network to deliver ECMC trials in the region.

 

Research Strategy

The primary strategic areas of the Liverpool ECMC are pancreatic cancer and haemato-oncology, with expertise in cancer biology and pharmacology to develop novel biomarkers of efficacy, resistance and drug safety.

Other areas of focus supported by local expertise are breast cancer with brain metastases, hepatobiliary cancers, head and neck cancers and uveal melanoma.

assays

Further Information

If you require any information which isn't on the website please contact the Liverpool ECMC Team via e-mail.